Yoshimura A, Horinaka M, Yaoi T, Ono H, et al. Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer. Br J Cancer 2024 May 31. doi: 10.1038/s41416-024-02727.
PMID: 38822146